Scientific name: Voacanga africana Stapf ex Scott-Elliot, formally described in 1894.

Family: Apocynaceae, the dogbane family. Relatives in this family include Tabernanthe iboga (the source of ibogaine), Catharanthus roseus (Madagascar periwinkle, source of vincristine and vinblastine), and Rauvolfia serpentina.

Common names: voacanga tree, small-fruited voacanga, sometimes marketed as African iboga or lesser iboga (a commercial label that overstates the pharmacological similarity). In São Tomé e Príncipe, healers know it as cata-manginga.

Native range: tropical Africa, from Senegal east to Sudan and Kenya, south to Angola, Zambia, and Mozambique. The plant grows as a small evergreen tree or large shrub up to 6 to 9 meters, with glossy opposite leaves, fragrant white or yellow flowers, and distinctive paired follicular fruits. All tissues exude a milky white latex.

Substance type: a plant in the broader iboga-alkaloid family. Voacanga contains compounds chemically related to those in Tabernanthe iboga but in different concentrations and proportions, which is why the two plants behave so differently in practice.

Voacanga africana contains one of the most complex alkaloid profiles documented in any African medicinal plant. A 2023 mass-spectrometry study identified 37 distinct compounds in the seeds alone. The dominant alkaloids fall into two structural families: iboga-type indoles, including voacangine (roughly 1.7% of root bark) and trace amounts of ibogaine itself, and iboga-vobasinyl bisindole alkaloids, including voacamine (around 3.7% of root bark) and voacamidine. The seeds are richest in tabersonine, a precursor used industrially to make vinpocetine for cognitive disorders.

The pharmacology is multi-receptor and unusually broad. Ibogaine, the alkaloid that draws most attention, acts primarily as an antagonist at NMDA glutamate receptors, the same receptor family targeted by ketamine. It also modulates serotonin transporters and dopamine signaling. In pharmacological terms it is a 'dirty drug' that touches many targets at once rather than binding selectively to one. UC Davis researchers established in 2023 that only the naturally occurring enantiomer of ibogaine produces its characteristic effects on neuronal growth, indicating a specific receptor mechanism rather than nonspecific cellular activity.

The bisindole alkaloids voacamine and related compounds were the first naturally occurring molecules confirmed as potent CB1 cannabinoid receptor antagonists, a distinct mechanism that may underlie some of voacanga's traditional use in inflammatory and pain conditions.

A crucial distinction shapes everything else on this page: ibogaine is present in Voacanga africana, but at concentrations of roughly 0.05 to 0.6% in commercial products, far below the levels needed for the classical ibogaine experience. The plant's commercial significance lies in voacangine, which can be chemically converted to ibogaine in a few synthetic steps. Most pharmaceutical-grade ibogaine in the world today is made this way, with voacanga seeds as the starting material.

Most people who meet Voacanga africana do so without realizing it. The seeds harvested from West African forests feed an industrial pharmaceutical supply chain, ending up as vinpocetine for circulation, vinblastine for chemotherapy, or semi-synthetic ibogaine for clinical addiction research. This is the dominant encounter, and it happens in factories rather than ceremonies.

A second encounter is older and quieter: traditional medicinal use across West and Central Africa. Healers in Cameroon, Ghana, Côte d'Ivoire, the Democratic Republic of Congo, and São Tomé e Príncipe have long used the root bark, stem bark, and leaves to treat diarrhea, parasitic infection, heart conditions, generalized inflammation, and what was historically described as madness or mental disorders. In some Bantu communities, dried leaves have been smoked for chronic headaches. These uses are ethnomedicinal, oriented toward the body and the mind together, and only loosely connected to the contemporary 'psychedelic' framing.

A third encounter, the most recent and the most contested, is through online ethnobotanical retailers selling powdered seeds or bark to consumers in North America and Europe. Whole plant material is typically taken orally as ground powder. Onset tends to be slow (30 to 120 minutes), the experience can extend across four to eight hours, and reported effects vary widely from barely perceptible to mildly altering. Importantly, the plant material at typical amounts contains too little ibogaine to produce the classical ibogaine state. What people report is mostly somatic, often nausea, and subtle.

A fourth and entirely different encounter happens in clinical or underground ibogaine programs, where the substance has been concentrated or synthesized from voacanga precursors. That is a separate experience, with separate risks, and should not be confused with the whole plant.

Long before any European botanist named the tree, healers across West and Central Africa worked with its bark and leaves. In Cameroon, Ghana, Côte d'Ivoire, and the Congo basin, Voacanga africana was used alongside its sister species Voacanga thouarsii to treat heart disease, leprosy, edema, convulsions in children, and conditions of the mind. In São Tomé e Príncipe, where it is called cata-manginga, healers prescribed it for inflammation and mental distress. These uses have been documented across multiple ethnobotanical surveys and align with what modern pharmacology now identifies in the plant's alkaloids.

Western science arrived late and missed most of this. In 1894, the botanist Otto Stapf provided the formal binomial Voacanga africana, and early colonial-era references dismissed the tree as little more than a rubber adulterant. After World War II, attention shifted. Pharmaceutical chemists studying related African plants noticed voacanga's alkaloid wealth. In 1955, two French chemists filed the first patent on a voacanga-derived heart medicine, opening a long extraction relationship in which raw seed left African ports and finished compounds entered European markets, with little benefit returning to source communities.

A different chapter began in 2007. A businessman in Accra, writing on Wikipedia under the username MrGoodGuy, edited the entry on Voacanga africana to describe it as a Ghanaian 'ceremonial psychedelic,' embedding a link to a website selling seeds. The link kept being removed and re-added. The narrative, however, spread quickly through ethnobotanical retailers, harm-reduction sites, and online forums. When researchers later interviewed people in Ghanaian towns where voacanga is harvested, most reported only that 'foreign companies use the seeds for medicines.' A few mentioned uses for hernias, parasites, or childbirth preparation. Almost no one described a psychedelic ceremony.

The modern story of voacanga, then, runs in two directions at once: a quiet pharmaceutical workhorse on one path, a constructed market identity on the other, with the actual ethnobotanical record sitting between them, often overlooked.

The most important risk associated with Voacanga africana is cardiac. Several of its alkaloids, including voacangine, voacamine, and voacamidine, have documented cardiac depressor activity. Ibogaine itself, present in trace amounts in the whole plant and in much larger amounts in concentrated preparations, produces bradycardia and QT interval prolongation, an alteration of the heart's electrical timing that can trigger a dangerous arrhythmia called Torsades de Pointes. Because ibogaine's active metabolite, noribogaine, has a much longer half-life than ibogaine itself, this cardiac risk can persist for days after a session, even after the acute experience has passed. Documented fatalities from concentrated ibogaine have included sudden cardiac death 24 to 76 hours after administration.

For whole plant material at typical amounts, this cardiac risk is meaningfully smaller, because the alkaloid load is meaningfully smaller. It is not zero. Anyone with a history of arrhythmia, QT abnormalities, hypertension, prior myocardial infarction, structural heart disease, or unexplained fainting should avoid voacanga entirely.

Drug interactions require care. Concurrent use with MAOIs is the highest-risk combination and should be avoided absolutely, with serotonin syndrome and hypertensive crisis as the concerns. SSRIs and tricyclic antidepressants raise serotonin syndrome risk and should not be combined without medical oversight. Cardiac medications including beta blockers, calcium channel blockers, and antiarrhythmics may stack with voacanga's own cardiac effects. Strong CNS depressants (alcohol, benzodiazepines, opioids) compound sedation and breathing risks.

Other physical considerations: some voacanga alkaloids produce convulsions in animal models, so anyone with a seizure history should avoid the plant. Hepatic metabolism runs largely through CYP2C19, which means liver impairment or interacting medications can alter the alkaloid load unpredictably.

Psychological considerations: NMDA antagonism (the same family of mechanisms ketamine uses) is associated with dissociative effects, and rarely with psychotic reactions in vulnerable individuals. Personal or family history of psychotic disorders is a reason to avoid this plant.

Plant material variability is itself a risk. A 2009 study by Japan's National Institute of Health Sciences found that many products sold as Voacanga africana were derived from related but different Voacanga species, with substantially different alkaloid profiles. What is in the bag may not match the label, even when the seller is acting in good faith.

For anyone choosing to engage with this plant, set, setting, and the presence of someone sober, attentive, and aware of how to respond to a cardiac event matter more than they would for most gentle substances.

What follows a voacanga experience is usually quieter than the literature on integration suggests. Whole plant sessions tend to leave gentle traces, a softness, mild fatigue, sometimes a clearer feeling for a day or so. The classical psychedelic afterglow, the deep insight that needs careful interpretation over weeks, is mostly absent here. Integration for whole plant work, then, is best treated as a small practice: rest, food, water, a quiet evening, and perhaps a few notes about anything that felt different.

For those who encounter voacanga through concentrated extracts or semi-synthetic ibogaine, integration takes a different shape. The clinical research on ibogaine for substance use disorder describes long aftereffects, sometimes weeks of altered perspective, increased gratitude, easier access to difficult emotions, and shifts in how people relate to old patterns. In those programs, integration involves prepared therapeutic relationships, structured follow-up, and the recognition that the day after the session is only the beginning of what the experience invites.

A few practices may help across both ends of the spectrum. Journaling in plain language, without trying to find the meaning right away. Time without screens in the days after, especially if the body still feels different. Rest as a real activity, not as the absence of one. Conversation with someone trusted, especially if the experience surfaced something tender. Patience, perhaps most of all, with the slow way that any altered state weaves itself into ordinary life.

Formal integration research specific to voacanga essentially does not exist. The frameworks people borrow come from psilocybin, MDMA, or ayahuasca traditions and may not always fit. It can help to hold any experience with this plant on its own terms, not as a smaller version of something else, and to notice what it actually offered rather than what the marketing suggested it should.

Voacanga's ecology is bound up with the supply chain that has grown around it. The pharmaceutical industry's increasing reliance on this plant is, on the surface, a conservation story: voacanga grows faster than the endangered Tabernanthe iboga, its bark can be harvested without killing the tree, and semi-synthetic ibogaine produced from voacangine reduces pressure on iboga's wild populations. Researchers have even developed closed-loop processes where waste from voacangine conversion fertilizes new voacanga plants. In principle, this is the kind of substitution conservation biology asks for.

The practice is more complicated. Voacanga is still harvested almost entirely from wild populations in Ghana and Côte d'Ivoire. The 1,600 tons of seeds that left African ports in 2009 were not from cultivated plantations, and large-scale cultivation outside the native range remains underdeveloped. Wild harvesting at industrial scale, even of an abundant species, has ecological consequences that have not been carefully studied.

The benefit-sharing question sits underneath all of this. Western pharmaceutical companies extract significant value from voacanga alkaloids, used in cancer drugs, dementia drugs, and increasingly in psychedelic medicine. The Nagoya Protocol on access and benefit sharing was designed to direct some of that value back to the source countries and communities. In voacanga's case, implementation has been thin. As semi-synthetic and total-synthetic production methods improve, the economic incentive to maintain any benefit-sharing relationship erodes further.

A second ethical layer concerns how the plant has been marketed in the consumer ethnobotanical space. The 2007 fabrication of voacanga as a 'ceremonial psychedelic' did real damage. It erased the actual traditional medicinal uses, invented an exoticized African ritual narrative for Western consumption, and built a commercial market on the back of an Orientalist fiction. African harvesters and communities remain mostly invisible in this story, even as their plant is sold with their identity attached.

For anyone considering engagement with this plant, the question is worth holding: where did this material come from, who benefited from its journey, and what story is being sold alongside the seeds?